Live Events

HDFC Bank Ltd announced that its Governance, Nomination and Remuneration Committee (GNRC) has granted 13,02,379 equity stock options under its ESOS – Plan H-2024 (ESOS 065). Each option has a face value of Re. 1/- and a grant price of Rs. 692.80. These options are convertible into one equity share each upon vesting and exercise. Vesting will occur in four stages over 48 months, with 25% vesting at 12, 24, 36, and 48 months from the grant date. Vested options must be exercised within four years of their vesting date, otherwise they will lapse. The grant is in compliance with SEBI regulations.

Jio Platforms Limited (JPL), a subsidiary of Reliance Industries Ltd, has finalized its Initial Public Offering (IPO) issue price at ₹1,119 per equity share. The company has also filed its prospectus dated October 24, 2026, with the Registrar of Companies, Gujarat at Ahmedabad. This IPO involves a fresh issue of up to 27 crore equity shares of face value ₹10 each. The subscription period for the IPO was from October 21 to October 23, 2026. The final issue price, including the anchor investor portion, is set at ₹1,119 per share.

Havells India Ltd has announced the exercise of 61,135 equity shares of Re. 1 each under the Havells Employees Stock Purchase Scheme 2022 (ESPS 2022). These shares were vested to eligible employees for the financial year 2025-26. The exercise was completed on October 24, 2026. The company noted that the total quantum of shares issued under this plan is insignificant relative to the total paid-up capital, resulting in negligible dilution in earnings per share. The pricing for these shares was determined at Rs. 1,302.10, the closing price on the day preceding the approval by the Nomination and Remuneration Committee.

Panchsheel Organics Ltd has announced that its Board of Directors, through a circular resolution dated October 24, 2026, has approved an application to the National Stock Exchange of India Limited (NSE) for listing its entire issued, subscribed, and paid-up equity share capital on the NSE Main Board. This will be done under the Direct Listing Route. The proposed listing is contingent upon compliance with all applicable laws, rules, and regulations, and the receipt of all necessary approvals and permissions from the NSE and other relevant authorities.

Panchsheel Organics Ltd announced that its Board of Directors, via a circular resolution dated October 24, 2026, has approved an application to the National Stock Exchange of India Limited (NSE) for listing of its entire issued, subscribed, and paid-up equity share capital on the NSE Main Board under the Direct Listing Route. This proposed listing is contingent upon compliance with all applicable laws, rules, and regulations, and the receipt of necessary approvals from the NSE and other relevant authorities.

Kajaria Ceramics Limited announced the opening of its trading window for dealing in the company's securities. This follows the closure of the trading window for the announcement of the outcome of the Board Meeting held on October 24, 2026. The outcome included the declaration of Unaudited Financial Results for the quarter/half year ended September 30, 2026, and the Interim Dividend for the financial year 2026-27. The trading window will reopen 48 hours after this announcement, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kajaria Ceramics Ltd announced an interim dividend of ₹12 per equity share for FY 2026-27, with a record date of October 29, 2026, and payment by November 22, 2026. The board also approved unaudited financial results for the quarter/half-year ended September 30, 2026. Additionally, the company approved significant expansion plans, including increasing production capacity at its Srikalahasti (Andhra Pradesh) plant by 12.50 MSM tiles (estimated ₹340 Crores investment) and at its Gailpur (Rajasthan) plant by 11 MSM tiles (estimated ₹180 Crores investment). A new tile adhesive manufacturing facility with a capacity of 9000 MT per month will be set up in Durgapur (West Bengal) with an estimated investment of ₹34 Crores. These expansions are expected to be completed by June 2027 (Srikalahasti), April 2027 (Gailpur), and December 2027 (Durgapur), respectively.

Kajaria Ceramics' Board of Directors approved an interim dividend of ₹12 per equity share for FY 2026-27, with a record date of October 29, 2026, and payment by November 22, 2026. The board also approved significant capacity expansions at its Srikalahasti (Andhra Pradesh) and Gailpur (Rajasthan) plants, adding 12.50 MSM and 11 MSM tiles respectively, with investments of ₹340 Crores and ₹180 Crores. Additionally, a new tile adhesive manufacturing facility with a capacity of 9000 MT per month will be set up in Durgapur (West Bengal) at an estimated cost of ₹34 Crores. The company also approved its unaudited financial results for the quarter/half year ended September 30, 2026.

Kajaria Ceramics Ltd's Board of Directors has approved an interim dividend of ₹12 per equity share for the financial year 2026-27. The record date for this dividend is October 29, 2026, with payments expected by November 22, 2026. The board also approved unaudited financial results for the quarter/half-year ended September 30, 2026. Additionally, the company greenlit significant expansion plans, including increasing production capacity at its Srikalahasti (Andhra Pradesh) plant by 12.50 MSM tiles (estimated ₹340 Crores investment, completion by June 2027) and at its Gailpur (Rajasthan) plant by 11 MSM tiles (estimated ₹180 Crores investment, completion by April 2027). A new manufacturing facility for tile adhesive in Durgapur (West Bengal) with a capacity of 9000 MT per month was also approved, requiring an estimated ₹34 Crores investment and expected to be operational by December 2027.

Arvaya Healthcare Ltd (formerly Bijoy Hans Limited) announced that its Executive Director, Mr. Bidari Kotresh Anilkumar, acquired 591,129 equity shares on October 24, 2026, through a preferential allotment. This transaction increases his total shareholding to 2,312,002 equity shares, representing 4.45% of the company's total capital. The acquisition was made pursuant to the company's preferential allotment of equity shares.